Novel way by NUS scientists to predict chemotherapy resistance in ovarian cancer patients

(National University of Singapore) Researchers from the National University of Singapore have found a way to predict if ovarian cancer patients will be resistant to chemotherapy. By using " automated " microscopy, they identified a protein that indicates the resistance of ovarian cancer cells to platinum chemotherapy. This breakthrough could improve the survival rate of ovarian cancer patients, as other treatments may be administered early.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news

Related Links:

AbstractWe evaluated the effectiveness, safety and efficacy of robotic interval debulking surgery (IDS) in advanced epithelial ovarian cancer (EOC) treated with neoadjuvant chemotherapy (NACT). We conducted a systematic review of the published relevant studies. Α total of 102 patients were evaluated. Mean operative time ranged from 164 to 312 min (mean ± SD: 246 ± 61 min) while mean estimated blood loss ranged from 106.9 to 262.5 ml (mean ± SD: 168 ± 68 ml) and postoperative blood transfusion rate was 19% (n&thinsp...
Source: Journal of Robotic Surgery - Category: Surgery Source Type: research
CONCLUSION: Hypoalbuminaemia at diagnosis is a poor prognostic factor in AOC. Normalization of serum albumin after NACT is a potential predictor of survival. PMID: 33021127 [PubMed - as supplied by publisher]
Source: Journal of Investigative Surgery - Category: Surgery Tags: J Invest Surg Source Type: research
Hynninen J Abstract OBJECTIVE: Human epididymis protein 4 (HE4) is a validated, complementary biomarker to cancer antigen 125 (CA125) for high grade serous ovarian carcinoma (HGSC). Currently, there are insufficient data on the utility of longitudinal HE4 measurement during HGSC treatment and follow up. We set to provide a comprehensive analysis on the kinetics and prognostic performance of HE4 with serial measurements during HGSC treatment and follow up. METHODS: This prospective study included 143 patients with advanced HGSC (ClinicalTrials.gov identifier: NCT01276574). Serum CA125 and HE4 were measured at...
Source: Acta Oncologica - Category: Cancer & Oncology Authors: Tags: Acta Oncol Source Type: research
Since type and duration of an appropriate adjuvant chemotherapy in early-stage ovarian cancer (OC) are still being debated, novel markers for a better stratification of these patients are of utmost importance for the design of an improved chemotherapeutical strategy. In contrast to numerous cancer studies on cellular proliferation based on the immunohistochemistry-driven evaluation of protein expression, we compared mRNA and protein expression of two independent markers of cellular proliferation, Ki-67 and Plk1, in a large cohort of 243 early-stage OC and their relationship with clinicopathological features and survival. B...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Cancer treatments can be damaging to the ovary, with implications for future fertility and reproductive lifespan. There is therefore a need for a biomarker than can usefully provide an assessment of the ovary and its potential for long-term function after cancer treatment, and ideally also be of value pre-treatment, for the prediction of post-treatment function. In this review we assess the value of anti-Müllerian hormone (AMH) in this context. Measurement of AMH at the time of cancer diagnosis has been shown to be predictive of whether or not there will remain some ovarian function post-treatment in women with breast...
Source: Frontiers in Endocrinology - Category: Endocrinology Source Type: research
Conditions:   Ovarian Cancer;   Low Grade Serous Carcinoma;   Primary Peritoneal Carcinoma;   Fallopian Tube Cancer Intervention:   Drug: Pembrolizumab Sponsors:   North Eastern German Society of Gynaecological Oncology;   Merck Sharp & Dohme Corp. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Advanced Ovarian Carcinoma;   Fallopian Tube Clear Cell Adenocarcinoma;   Fallopian Tube Endometrioid Tumor;   Fallopian Tube Serous Neoplasm;   Fallopian Tube Transitional Cell Carcinoma;   Ovarian Clear Cell Adenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   O varian Serous Adenocarcinoma;   Ovarian Transitional Cell Carcinoma;   Primary Peritoneal Clear Cell Adenocarcinoma;   Primary Peritoneal...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Ovarian Cancer;   Low Grade Serous Carcinoma;   Primary Peritoneal Carcinoma;   Fallopian Tube Cancer Intervention:   Drug: Pembrolizumab Sponsors:   North Eastern German Society of Gynaecological Oncology;   Merck Sharp & Dohme Corp. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Advanced Ovarian Carcinoma;   Fallopian Tube Clear Cell Adenocarcinoma;   Fallopian Tube Endometrioid Tumor;   Fallopian Tube Serous Neoplasm;   Fallopian Tube Transitional Cell Carcinoma;   Ovarian Clear Cell Adenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   O varian Serous Adenocarcinoma;   Ovarian Transitional Cell Carcinoma;   Primary Peritoneal Clear Cell Adenocarcinoma;   Primary Peritoneal...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Ovarian Cancer;   Low Grade Serous Carcinoma;   Primary Peritoneal Carcinoma;   Fallopian Tube Cancer Intervention:   Drug: Pembrolizumab Sponsors:   North Eastern German Society of Gynaecological Oncology;   Merck Sharp & Dohme Corp. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Chemotherapy | Ovarian Cancer | Ovaries | Singapore Health